Timothy Jay Price
Queen Elizabeth Hospital · 759 works · 34,388 citations · h-index 63
Top works
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Cetuximab for the Treatment of Colorectal Cancer
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- Management of gastric cancer in Asia: resource-stratified guidelines
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer